{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:38:12Z","timestamp":1785523092024,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>To review evidence around the value and challenges of surgery for recurrent epithelial ovarian cancer (ROC). Both cytoreductive and palliative aspects will be addressed<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Prospective and retrospective evidence demonstrates a significantly longer remission derived from the combination of surgical and systemic modalities as opposed to systemic treatment alone in carefully selected ROC-patients who have relapsed more than 6\u00a0months from the end of their 1st line platinum-based chemotherapy. Nevertheless, this benefit appears to be limited when total macroscopic tumor clearance is not achieved. Selection algorithms to identify optimal surgical candidates are of paramount importance to prevent surgical morbidity without the equivalent oncological benefit. In the palliative setting, the risks and benefits of salvage surgery need to be counterbalanced with the advances of conservative techniques for optimal care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Well-defined selection algorithms to identify those who will benefit from surgery in the relapsed setting appear to be the key to oncologic and surgical success.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-023-01480-8","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T07:02:08Z","timestamp":1702450928000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgery for Recurrent Epithelial Ovarian Cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Gerda","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Yagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Joon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"9","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1245\/s10434-019-07516-3","volume":"26","author":"M Hall","year":"2019","unstructured":"Hall M, Savvatis K, Nixon K, et al. Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome. Ann Surg Oncol. 2019;26(9):2943\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1200\/JCO.21.02085","volume":"40","author":"MH Baek","year":"2022","unstructured":"\u2022 Baek MH, Park EY, Ha HI, Park SY, Lim MC, Fotopoulou C, Bristow RE. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis. J Clin Oncol. 2022;40(15):1659\u201370. https:\/\/doi.org\/10.1200\/JCO.21.02085.\u00a0This meta-analysis presents all evidence around the value of secondary cytoreductive surgery in epithelial ovarian cancer relapse. Eligible indications and patients selection algorithms are being discussed here.","journal-title":"J Clin Oncol"},{"key":"1480_CR3","doi-asserted-by":"publisher","unstructured":"Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO\u2013ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Int J Gynecol Cancer. 2019: ijgc-2019\u2013000308. https:\/\/doi.org\/10.1136\/ijgc-2019-000308.","DOI":"10.1136\/ijgc-2019-000308"},{"key":"1480_CR4","doi-asserted-by":"publisher","unstructured":"Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayasamy Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S; CovidSurg Gynecological Cancer Collaborators. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study Am J Obstet Gynecol 2022: 227(5):735.e1\u2013735.e25. https:\/\/doi.org\/10.1016\/j.ajog.2022.06.052","DOI":"10.1016\/j.ajog.2022.06.052"},{"key":"1480_CR5","doi-asserted-by":"publisher","unstructured":"Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. COVIDSurg Collaborative. Lancet Oncol 2021: 22(11):1507\u20131517. https:\/\/doi.org\/10.1016\/S1470-2045(21)00493-9","DOI":"10.1016\/S1470-2045(21)00493-9"},{"issue":"8","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.clon.2018.04.006","volume":"30","author":"M Bommert","year":"2018","unstructured":"Bommert M, Harter P, Heitz F, du Bois A. When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol). 2018;30(8):493\u20137. https:\/\/doi.org\/10.1016\/j.clon.2018.04.006.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"22","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"00173","DOI":"10.1016\/j.jviscsurg.2022.11.002","volume":"S1878\u20137886","author":"V Jain","year":"2022","unstructured":"Jain V, Debnath S, Sharma A, Kamboj M, Mohanty A, Rawal S. Isolated lymph node recurrence in epithelial ovarian cancer - management and outcome. J Visc Surg. 2022;S1878\u20137886(22):00173\u20134. https:\/\/doi.org\/10.1016\/j.jviscsurg.2022.11.002.","journal-title":"J Visc Surg"},{"key":"1480_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929\u201339.","journal-title":"N Engl J Med"},{"key":"1480_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439\u201349.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1480_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"\u2022\u2022 Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgard BJ, Selle F, Guyon F, Pomel C, L\u00e9curu F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A. DESKTOP III Investigators Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2103294. This is the first prospective randomised trial in epithelial ovarian cancer relapse to demonstrate both progression-free and overall survival benefit in patients who undergo surgery and chemotherapy versus chemotherapy alone. This study has had a significant impact on treatment guidelines internationally.","journal-title":"N Engl J Med"},{"key":"1480_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265\u201374.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Trop\u00e9 CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890\u20136. https:\/\/doi.org\/10.1038\/bjc.2011.328.","journal-title":"Br J Cancer"},{"issue":"2","key":"1480_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289\u201395.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schr\u00f6der W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Ann Surg Oncol. 2006;13(12):1702\u201310. https:\/\/doi.org\/10.1245\/s10434-006-9058-0.","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"1480_CR15","first-page":"00206","volume":"S0090\u20138258","author":"N Bizzarri","year":"2022","unstructured":"Bizzarri N, Marchetti C, Conte C, et al. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery. Gynecol Oncol. 2022;S0090\u20138258(22):00206\u201312.","journal-title":"Gynecol Oncol"},{"key":"1480_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ygyno.2021.10.080","volume":"164","author":"AM Goldberg","year":"2022","unstructured":"Goldberg AM, Kim SR, Fazelzad R, et al. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: a systematic review and meta-analysis. Gynecol Oncol. 2022;164:212\u201320.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1480_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1808424.","journal-title":"N Engl J Med"},{"key":"1480_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2004.07.033","volume":"95","author":"MM Leitao Jr","year":"2004","unstructured":"Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95:181\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1480_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2006.08.037","volume":"104","author":"AK Karam","year":"2007","unstructured":"Karam AK, Santillan A, Bristow RE, Giuntoli R 2nd, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol. 2007;104(2):377\u201380.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1480_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jso.21146","volume":"98","author":"M Gultekin","year":"2008","unstructured":"Gultekin M, Velipa\u015fao\u011flu M, Aksan G, Dursun P, Dogan NU, Yuce K, Ayhan A. A third evaluation of tertiary cytoreduction. J Surg Oncol. 2008;98(7):530\u20134.","journal-title":"J Surg Oncol"},{"key":"1480_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ygyno.2010.01.046","volume":"117","author":"KK Shih","year":"2010","unstructured":"Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010;117:330\u20135.","journal-title":"Gynecol Oncol"},{"key":"1480_CR22","doi-asserted-by":"publisher","unstructured":"H\u0131zl\u0131 D, Boran N, Y\u0131lmaz S, Turan T, Alt\u0131nba\u015f SK, Celik B, K\u00f6se MF. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2012;163(1):71\u20135. https:\/\/doi.org\/10.1016\/j.ejogrb.2012.03.018","DOI":"10.1016\/j.ejogrb.2012.03.018"},{"key":"1480_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1245\/s10434-010-1245-3","volume":"18","author":"C Fotopoulou","year":"2011","unstructured":"Fotopoulou C, Richter R, Braicu IE, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol. 2011;18:49\u201357.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1480_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","volume":"20","author":"C Fotopoulou","year":"2013","unstructured":"Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli,. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. J Ann Surg Oncol. 2013;20(4):1348\u201354. https:\/\/doi.org\/10.1245\/s10434-012-2673-z.","journal-title":"J. Ann Surg Oncol"},{"issue":"1","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ygyno.2017.07.008","volume":"147","author":"F Falcone","year":"2017","unstructured":"Falcone F, Scambia G, Benedetti Panici P, Signorelli M, Cormio G, Giorda G, Bogliolo S, Marinaccio M, Ghezzi F, Rabaiotti E, Breda E, Casella G, Fanfani F, Di Donato V, Leone Roberti Maggiore U, Greggi S. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: a multicentre MITO retrospective study. Gynecol Oncol. 2017;147(1):66\u201372. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.008.","journal-title":"Gynecol Oncol"},{"key":"1480_CR26","doi-asserted-by":"publisher","unstructured":"Jalid Sehouli, Christina Fotopoulou, Ignace Vergote, Alexander Reuss, Gwenael Ferron, Werner Meier, Stefano Greggi, Berit J. Mosgaard, Frederic Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Kristina Hellmann, Jae-Weon Kim, Margarita Romeo, Francesco Raspagliesi, Brynhildur Eyj\u00f3lfsd\u00f3ttir, Andreas Du Bois, Philipp Harter. Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: a subanalysis of the DESKTOP III trial. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5520 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 5520\u20135520.","DOI":"10.1200\/JCO.2022.40.16_suppl.5520"},{"issue":"1","key":"1480_CR27","doi-asserted-by":"publisher","first-page":"Pe18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. The Lancet Oncol. 2020;21(1):Pe18-e28.","journal-title":"The Lancet Oncol"},{"issue":"3","key":"1480_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","volume":"101","author":"R Lazzari","year":"2018","unstructured":"Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, Comi S, Pansini F, Fodor C, Orecchia R, Tomao F, Parma G, Colombo N, Jereczek-Fossa BA. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys. 2018;101(3):650\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.03.058. (Epub 2018 Apr 4).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","volume":"25","author":"G Macchia","year":"2020","unstructured":"Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D\u2019Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist. 2020;25(2):e311\u201320. https:\/\/doi.org\/10.1634\/theoncologist.2019-0309.","journal-title":"Oncologist"},{"issue":"23","key":"1480_CR30","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.21.00605","volume":"39","author":"O Zivanovic","year":"2021","unstructured":"\u2022\u2022 Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y. O\u2019Cearbhaill RE (2021) Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 2021;39(23):2594\u2013604. https:\/\/doi.org\/10.1200\/JCO.21.00605.\u00a0This is the only so far published prospective randomized trial in epithelial ovarian cancer relapse that addresses the impact of HIPEC in addition to secondary cytoreduction. This study has shown that no additional survival benefit is derived from HIPEC, and therefore, HIPEC in that setting should only be performed within clinical trials.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","volume":"167","author":"SI Kim","year":"2022","unstructured":"Kim SI, Kim JH, Lee S, Cho H, van Driel WJ, Sonke GS, Bristow RE, Park SY, Fotopoulou C, Gynecol Lim MC., Oncol,. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis. Gynecologic Oncology. 2022;167(3):547\u201356. https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.010.","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"1480_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1089\/jpm.2017.0679","volume":"21","author":"BA Davidson","year":"2018","unstructured":"Davidson BA, Moss HA, Kamal AH. Top 10 tips palliative care clinicians should know when caring for patients with ovarian cancer. J Palliat Med. 2018;21(2):250\u20134. https:\/\/doi.org\/10.1089\/jpm.2017.0679.","journal-title":"J Palliat Med"},{"issue":"12","key":"1480_CR33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","volume":"2","author":"RA Burger","year":"2014","unstructured":"Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2014;2(12):1210\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1480_CR34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00404-021-06237-x","volume":"305","author":"R Armbrust","year":"2022","unstructured":"Armbrust R, Chekerov R, Sander S, Biebl M, Chopra S, Krell J, Rinne N, Nixon K, Fotopoulou C, Arch Sehouli J, Obstet Gynecol. Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. Archives Gynecol Obstetrics. 2022;305(4):963\u20138. https:\/\/doi.org\/10.1007\/s00404-021-06237-x.","journal-title":"Archives Gynecol Obstetrics"},{"issue":"8","key":"1480_CR35","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1097\/IGC.0b013e31829f81ca","volume":"23","author":"C Fotopoulou","year":"2013","unstructured":"Fotopoulou C, Braicu EI, Kwee SL, Kuhberg M, Richter R, Pietzner K, Feldheiser A, Bahra M, Schmidt SC. Sehouli (2013) Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome. J Int J Gynecol Cancer. 2013;23(8):1495\u2013500. https:\/\/doi.org\/10.1097\/IGC.0b013e31829f81ca.","journal-title":"J Int J Gynecol Cancer"},{"issue":"1","key":"1480_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2012.12.028","volume":"129","author":"SJ Mooney","year":"2013","unstructured":"Mooney SJ, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013;129(1):107\u201312.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1480_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00404-020-05545-y","volume":"302","author":"M Jin","year":"2020","unstructured":"Jin M, Shen F, Li M, Chen Y. Palliative treatment for bowel obstruction in ovarian cancer: a meta-analysis. Arch Gynecol Obstet. 2020;302(1):241\u20138. https:\/\/doi.org\/10.1007\/s00404-020-05545-y.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"1480_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/ijgc-2019-001058","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou C, Haidopoulos D. Extraperitoneal en bloc intestinal resection as palliative surgery for treatment refractory bowel obstruction in ovarian cancer relapse. Int J Gynecol Cancer. 2020;30(5):711. https:\/\/doi.org\/10.1136\/ijgc-2019-001058.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1480_CR39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00404-017-4484-8","volume":"296","author":"Y Segev","year":"2017","unstructured":"Segev Y, Segev L, Schmidt M, Auslender R, Lavie O. Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review. Arch Gynecol Obstet. 2017;296(4):691\u2013700.","journal-title":"Arch Gynecol Obstet"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01480-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:42:52Z","timestamp":1707550972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01480-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"22 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christina Fotopoulou has received honoraria for Consulting or Advisory Role from GlaxoSmithKline, Roche\/Genentech, Clovis Oncology, AstraZeneca, Global Oncology One, Aptitude Health, and Eisai.Myong Cheol Lim has received honoraria for Consulting or Advisory Role: GI Innovation, Boryung, AstraZeneca, Takeda; research funding: CKD Pharm, AstraZeneca, Clovis Oncology, and OncoQuest.Ane Gerda Eriksson received speakers honorarium from Intuitive Surgical and Astra Zeneca.No other potential conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}